+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

CB-839 (Calithera Biosciences) Drug Overview 2019

  • ID: 4775190
  • Report
  • 14 pages
  • Datamonitor Healthcare
1 of 2
Drug Overview
Cancer cells are known to rely on glycolysis as an energy source. CB-839 (Calithera Biosciences) inhibits the glutaminase enzyme, reducing the ability of cancer cells to utilize glutamine in this biochemical pathway, thereby reducing cell proliferation and tumor growth.

If approved, CB-839 will be the first glutaminase inhibitor approved for the treatment of renal cell carcinoma (RCC). This novel mechanism of action could place CB-839 in a unique position in the RCC market and provide physicians with an alternative treatment option. CB-839 is being investigated in combination with either Afinitor (everolimus; Novartis) or Cabometyx (cabozantinib; Exelixis/Ipsen/Takeda) for previously treated advanced RCC patients, suggesting it will not compete with the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) therapies being developed for first-line use. CB-839 is being developed by Calithera Biosciences, a company that is yet to bring an oncology product to market. Due to Calithera’s limited geographic scope, the author expects the company to look for partners to market CB-839 in Japan and the EU.

Analyst Outlook
If approved, CB-839 (Calithera Biosciences) will be the first glutaminase inhibitor approved for the treatment of renal cell carcinoma (RCC). This novel mechanism of action could place CB-839 in a unique position in the RCC market and provide physicians with an alternative treatment option. CB-839 is being investigated in combination with either Afinitor (everolimus; Novartis) or Cabometyx (cabozantinib; Exelixis/Ipsen/Takeda) for previously treated advanced RCC patients, suggesting it will not compete with the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) therapies being developed for first-line use. CB-839 is being developed by Calithera Biosciences, a company that is yet to bring an oncology product to market. Due to Calithera’s limited geographic scope, the author expects the company to look for partners to market CB-839 in Japan and the EU.
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
  • Drug Overview
  • Product Profiles
  • CB-839: Renal cell carcinoma (RCC)
LIST OF FIGURES
Figure 1: CB-839 for RCC – SWOT analysis
Figure 2: The author's drug assessment summary of CB-839 for RCC
Figure 3: The author's drug assessment summary of CB-839 for RCC
Figure 4: CB-839 sales for RCC in the US, 2017–26

LIST OF TABLES
Table 1: CB-839 drug profile
Table 2: CB-839 Phase II trials in RCC
Table 3: CB-839 sales for RCC in the US ($m), 2017–26
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll